Company Description
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 1990 |
| IPO Date | Jun 30, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 229 |
| CEO | Harout Semerjian |
Contact Details
Address: 919 East Hillsdale Boulevard, Suite 250 Foster City, California 94404 United States | |
| Phone | 650 473 7700 |
| Website | geron.com |
Stock Details
| Ticker Symbol | GERN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000886744 |
| CUSIP Number | 374163103 |
| ISIN Number | US3741631036 |
| Employer ID | 75-2287752 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Harout Semerjian | Chief Executive Officer, President and Director |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial and Accounting Officer |
| Dr. Joseph Emile Eid M.D. | Executive Vice President of Research and Development and Chief Medical Officer |
| Shanthakumar Tyavanagimatt | Senior Vice President and Chief Technical Officer |
| Dawn Schottlandt CFA | Senior Vice President of Investor Relations and Corporate Affairs |
| Aron Feingold | Vice President of Investor Relations and Corporate Communications |
| Shannon T. Odam | Executive Vice President and Chief People Officer |
| Bryan Ridgell | Senior Vice President of Portfolio and Project Management and Chief of Staff |
| Ahmed ElNawawi | Executive Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | SCHEDULE 13G | Filing |
| Mar 2, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 2, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 6, 2026 | 8-K | Current Report |
| Dec 16, 2025 | 8-K | Current Report |
| Dec 15, 2025 | 144 | Filing |
| Nov 7, 2025 | 10-Q | Quarterly Report |